Exogenous Oncostatin M induces Cardiac Dysfunction, Musculoskeletal Atrophy, and Fibrosis. (November 2022)

• Record Type: Journal Article
• Authors: Jengelley, Daenique H.A.; Wang, Meijing; Narasimhan, Ashok; Rupert, Joseph E.; Young, Andrew R.; Zhong, Xiaoling; Horan, Daniel J.; Robling, Alexander G.; Koniaris, Leonidas G.; Zimmers, Teresa A.
• Is Part Of: Cytokine. Volume 159(2022)
• Publication Date: 2022-11
• Subjects: Oncostatin M -- Interleukin-6 -- Skeletal Muscle -- Bone -- AAV -- Atrophy -- Fibrosis -- Inflammation -- IL6ST/GP130 -- Cachexia -- Cardiac Dysfunction; OSM Oncostatin M -- IL-6 Interleukin-6 -- AAV Adeno-Associated Virus -- IL6ST IL-6 Signal Transducer; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2022.155972
• Languages: English
• ISSNs: 1043-4666

Abstract

Highlights: Exogenous OSM mediates muscle wasting and bone wasting in vivo. Exogenous OSM induces cardiac dysfunction and inflammation. Effects of OSM are not dependent on IL-6. Abstract: Musculoskeletal diseases such as muscular dystrophy, cachexia, osteoarthritis, and rheumatoid arthritis impair overall physical health and reduce survival. Patients suffer from pain, dysfunction, and dysmobility due to inflammation and fibrosis in bones, muscles, and joints, both locally and systemically. The Interleukin-6 (IL-6) family of cytokines, most notably IL-6, is implicated in musculoskeletal disorders and cachexia. Here we show elevated circulating levels of OSM in murine pancreatic cancer cachexia and evaluate the effects of the IL-6 family member, Oncostatin M (OSM), on muscle and bone using adeno-associated virus (AAV) mediated over-expression of murine OSM in wildtype and IL-6 deficient mice. Initial studies with high titer AAV-OSM injection yielded high circulating OSM and IL-6, thrombocytosis, inflammation, and 60% mortality without muscle loss within 4 days. Subsequently, to mimic OSM levels in cachexia, a lower titer of AAV-OSM was used in wildtype and Il6 null mice, observing effects out to 4 weeks and 12 weeks. AAV-OSM caused muscle atrophy and fibrosis in the gastrocnemius, tibialis anterior, and quadriceps of the injected limb, but these effects were not observed on the non-injected side. In contrast, OSM induced both local and distant trabecular bone loss as shown by reduced bone volume, trabecular number, and thickness, and increased trabecular separation. OSM caused cardiac dysfunction including reduced ejection fraction and reduced fractional shortening. RNA-sequencing of cardiac muscle revealed upregulation of genes related to inflammation and fibrosis. None of these effects were different in IL-6 knockout mice. Thus, OSM induces local muscle atrophy, systemic bone loss, tissue fibrosis, and cardiac dysfunction independently of IL-6, suggesting a role for OSM in musculoskeletal conditions with these characteristics, including cancer cachexia.